scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Walleye Capital LLC

Walleye Capital LLC raised its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 27.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 475,555 shares of the company’s stock after purchasing an additional 101,148 shares during the quarter. Walleye Capital LLC owned 0.95% of scPharmaceuticals worth $2,169,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of SCPH. BNP Paribas Financial Markets lifted its holdings in scPharmaceuticals by 116.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock worth $26,000 after buying an additional 3,101 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in scPharmaceuticals during the third quarter worth $57,000. MetLife Investment Management LLC increased its stake in scPharmaceuticals by 135.0% during the third quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock valued at $77,000 after purchasing an additional 9,752 shares during the last quarter. Virtu Financial LLC bought a new stake in scPharmaceuticals during the first quarter valued at $90,000. Finally, Balanced Rock Investment Advisors LLC raised its holdings in shares of scPharmaceuticals by 10.3% during the second quarter. Balanced Rock Investment Advisors LLC now owns 63,130 shares of the company’s stock worth $275,000 after purchasing an additional 5,882 shares during the period. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SCPH has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research report on Thursday, November 14th. Craig Hallum dropped their price target on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

scPharmaceuticals Stock Down 3.0 %

scPharmaceuticals stock opened at $3.60 on Wednesday. The firm has a market capitalization of $180.14 million, a P/E ratio of -1.89 and a beta of 0.14. The company has a 50-day simple moving average of $4.06 and a 200-day simple moving average of $4.39. scPharmaceuticals Inc. has a one year low of $3.08 and a one year high of $6.71. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.